This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

This invention relates to the use of the combination of 25-hydroxyvitamin D3 (25-OH D3) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian 5 syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.

This invention relates to the use of the combination of 25-hydroxyvitamin D3 (25-OH D3) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian 5 syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.

This invention relates to the use of the combination of 25-hydroxyvitamin D3 (25-OH D3) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian 5 syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.

This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

The present disclosure relates to a pharmaceutical composition for the prevention or treatment of arthritis, the composition including a sargahydroquinoic acid as an active ingredient. The sargahydroquinoic acid according to the present disclosure has an excellent activity to reduce or inhibit the activity of IL-1, IL-6, or TNF-, which is an inflammatory cytokine, and has an excellent effect of ameliorating arthritis in an arthritis animal model, and thus can be advantageously used as a composition for the treatment of arthritis. In addition, the sargahydroquinoic acid causes neither drug toxicity and side effects, and thus can be safely used even when taken for a long period of time, and has a stable effect even in the body.

The present disclosure relates to a pharmaceutical composition for the prevention or treatment of arthritis, the composition including a sargahydroquinoic acid as an active ingredient. The sargahydroquinoic acid according to the present disclosure has an excellent activity to reduce or inhibit the activity of IL-1, IL-6, or TNF-, which is an inflammatory cytokine, and has an excellent effect of ameliorating arthritis in an arthritis animal model, and thus can be advantageously used as a composition for the treatment of arthritis. In addition, the sargahydroquinoic acid causes neither drug toxicity and side effects, and thus can be safely used even when taken for a long period of time, and has a stable effect even in the body.